In the European Union,<unk>  is indicated for the treatment of coronavirus disease 2019 (COVID‑19) in adults and adolescents (aged twelve years and older with body weight at least ) with pneumonia requiring supplemental oxygen. In the United States,<unk>  is indicated for use in adults and adolescents (aged twelve years and older with body weight at least ) for the treatment of COVID‑19 requiring hospitalization. In January 2022, the FDA expanded the indication for<unk>  to include its use in non-hospitalized adults and adolescents with positive results of direct SARS-CoV-2 viral testing, and who are not hospitalized and have mild-to-moderate COVID‑19, and are at high risk for progression to severe COVID‑19, including hospitalization or death. In November 2020, the FDA issued an emergency use authorization (EUA) for the combination of baricitinib with<unk> , for the treatment of suspected or laboratory confirmed COVID‑19 in hospitalized people two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Remdesivir
Coronavir
Entecavir
Saquinavir
Letermovir
Odalasvir
Maribavir
Fostemsavir